Immutep is an emerging international biotechnology company focused on developing innovative immunotherapeutic products for the treatment of cancer and autoimmune diseases. With operations in Australia, Germany, and France, Immutep is committed to providing cutting-edge treatment options to patients. The company is publicly traded on the ASX and NASDAQ, reflecting its growth and dedication to advancing healthcare through scientific research and development.